Abstract
Objective: The use of dipeptidyl-peptidase 4 (DPP4) inhibitors and glucagon like peptide 1 (GLP1) analogues for the treatment of diabetic mellitus (DM) type 2 is growing. Currently some of these agents have been approved in combination with insulin. Methods: We considered randomised controlled trials (RCTs) evaluating GLP1 analogues or DDP4 inhibitors combined with basal insulin in diabetic patients. We were limited to trials published in English language. Results: PubMed search retrieved 207 items. After excluding irrelevant items we ended with 7 eligible studies with 1808 participants. Mean baseline HbA1c was 8.5% and median follow up was 24 weeks. Exenatide combined with insulin was used in 2 studies; DPP4 inhibitors were used in 5 studies (2 with sitagliptin, 1 with saxagliptin, 1 with vildagliptin and 1 with alogliptin). Conclusion: Incretin-based therapies combined with basal insulin are able to reduce HbA1c by 0.5-0.7%. DPP4 inhibitors have no significant effect on weight, whereas GLP1 analogues reduced weight by 1-2 kg. Hypoglycaemia rates were generally comparable in all treatment groups. These are promising results, but the available evidence is limited. This is a poorly investigated field with few RCTs. New studies focusing on head-to-head comparisons with short-acting insulin on top of basal insulin are needed.
Keywords: Exenatide, liraglutide, sitagliptin, saxagliptin, vildagliptin, alogliptin, insulin, diabetes mellitus.
Current Vascular Pharmacology
Title:Combination Therapies of DPP4 Inhibitors and GLP1 Analogues with Insulin in Type 2 Diabetic Patients: A Systematic Review
Volume: 11 Issue: 6
Author(s): Evangelos C. Rizos, Evangelia E. Ntzani, Nikolaos Papanas, Vasilis Tsimihodimos, Zoi Mitrogianni, Efstratios Maltezos and Moses S. Elisaf
Affiliation:
Keywords: Exenatide, liraglutide, sitagliptin, saxagliptin, vildagliptin, alogliptin, insulin, diabetes mellitus.
Abstract: Objective: The use of dipeptidyl-peptidase 4 (DPP4) inhibitors and glucagon like peptide 1 (GLP1) analogues for the treatment of diabetic mellitus (DM) type 2 is growing. Currently some of these agents have been approved in combination with insulin. Methods: We considered randomised controlled trials (RCTs) evaluating GLP1 analogues or DDP4 inhibitors combined with basal insulin in diabetic patients. We were limited to trials published in English language. Results: PubMed search retrieved 207 items. After excluding irrelevant items we ended with 7 eligible studies with 1808 participants. Mean baseline HbA1c was 8.5% and median follow up was 24 weeks. Exenatide combined with insulin was used in 2 studies; DPP4 inhibitors were used in 5 studies (2 with sitagliptin, 1 with saxagliptin, 1 with vildagliptin and 1 with alogliptin). Conclusion: Incretin-based therapies combined with basal insulin are able to reduce HbA1c by 0.5-0.7%. DPP4 inhibitors have no significant effect on weight, whereas GLP1 analogues reduced weight by 1-2 kg. Hypoglycaemia rates were generally comparable in all treatment groups. These are promising results, but the available evidence is limited. This is a poorly investigated field with few RCTs. New studies focusing on head-to-head comparisons with short-acting insulin on top of basal insulin are needed.
Export Options
About this article
Cite this article as:
Rizos C. Evangelos, Ntzani E. Evangelia, Papanas Nikolaos, Tsimihodimos Vasilis, Mitrogianni Zoi, Maltezos Efstratios and Elisaf S. Moses, Combination Therapies of DPP4 Inhibitors and GLP1 Analogues with Insulin in Type 2 Diabetic Patients: A Systematic Review, Current Vascular Pharmacology 2013; 11 (6) . https://dx.doi.org/10.2174/15701611113119990103
DOI https://dx.doi.org/10.2174/15701611113119990103 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Alzheimer Disease and Diabetes Mellitus: Do They have Anything in Common?
Current Alzheimer Research Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction
Current Topics in Medicinal Chemistry Antiplatelet and Antileukocyte Effects of Cardiovascular,Immunomodulatory and Chemotherapeutic Drugs
Cardiovascular & Hematological Agents in Medicinal Chemistry Alzheimer’s Disease is Associated with Increased Risk of Osteoporosis: The Chongqing Aging Study
Current Alzheimer Research Association of Serum Uric Acid and Metabolic Syndrome in Type 2 Diabetes
Current Diabetes Reviews Glycemic Variability, Oxidative Stress, and Impact on Complications Related to Type 2 Diabetes Mellitus
Current Diabetes Reviews The Triad: Erectile Dysfunction - Endothelial Dysfunction - Cardiovascular Disease
Current Pharmaceutical Design Evaluation of Mucin as a Release Enhancer for Rectal Delivery of Glibenclamide
Current Drug Delivery Possible Underestimation by Sports Medicine of the Effects of Early Physical Exercise Practice on the Prevention of Diseases in Adulthood
Current Diabetes Reviews Melatonin in Pregnancy: Effects on Brain Development and CNS Programming Disorders
Current Pharmaceutical Design Management of the Metabolic Syndrome as a Strategy for Preventing the Macrovascular Complications of Type 2 Diabetes: Controversial Issues
Current Diabetes Reviews Antidyslipidemic Capacity of <i>Cleome arabica</i> (L.) in Streptozotocin-Induced Diabetic Rats
Cardiovascular & Hematological Agents in Medicinal Chemistry Longitudinal Association between White Matter Hyperintensities and White Matter Beta-Amyloid Deposition in Cognitively Unimpaired Elderly
Current Alzheimer Research Stem Cell and Tissue Engineering Therapies for Ocular Regeneration
Current Stem Cell Research & Therapy Investigating the Associations between Mediterranean Diet, Physical Activity and Living Environment with Childhood Asthma using Path Analysis
Endocrine, Metabolic & Immune Disorders - Drug Targets Targets for the Treatment of Erectile Dysfunction: Is NO/cGMP Still the Answer?
Recent Patents on Cardiovascular Drug Discovery Hydroxyl Radical Mediates Oxidative Modification of Caprine Alpha-2 Macroglobulin
Protein & Peptide Letters Glucose Control and Use of Continuous Glucose Monitoring in the Intensive Care Unit: A Critical Review
Current Diabetes Reviews Mechanisms of Herb-Induced Nephrotoxicity
Current Medicinal Chemistry Progress in Nutritional and Health Profile of Milk and Dairy Products: A Novel Drug Target
Endocrine, Metabolic & Immune Disorders - Drug Targets